Clinical Trial Details
| Trial ID: | L1244 |
| Source ID: | NCT03630029 |
| Associated Drug: | Fes And Snpp |
| Title: | RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD |
| Acronym: | |
| Status: | WITHDRAWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Acute Kidney Injury |
| Interventions: | DRUG: FeS and SnPP |
| Outcome Measures: | Primary: Effect of RBT-1 on biomarkers of cytoprotective activity, Measuring Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL-10, and Heme Oxygenase-1, the P21 biomarker systemic levels, 7 days | Secondary: Adverse events, Safety and tolerability of RBT-1 in Healthy Volunteers and subjects with CKD, 7 days|Establish the optimal dose for future development, The highest dose of RBT-1 with the best safety and tolerability will be determined, 60 days |
| Sponsor/Collaborators: | Sponsor: Renibus Therapeutics, Inc. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 0 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION |
| Start Date: | 2018-09-15 |
| Completion Date: | 2019-03-31 |
| Results First Posted: | |
| Last Update Posted: | 2020-05-11 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT03630029 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|